You are here:

Tiotropium bromide (Spiriva®)


Recommended for general use within NHS Scotland for the maintenance treatment of chronic obstructive pulmonary disease (COPD).


In clinical trials, tiotropium demonstrated superior efficacy to ipratropium and salmeterol in improving lung function (FEV1). Generally, it has greater efficacy than ipratropium, and similar efficacy to salmeterol in improving dyspnoea, the use of rescue medication, the frequency of COPD exacerbations and hospitalisation due to exacerbations.

Drug Details

Drug Name: Tiotropium bromide (Spiriva®)
SMC Drug ID: 19/02
Manufacturer: Boehringer Ingelheim Ltd
Indication: Chronic obstructive pulmonary disease
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Accepted
Date Advice Published: 6 December 2002